
Contents

Foreword by Steven B. Karch	v
Preface	ix
Contributors	xxv
Product Identification Guide	following p.134

PART I LEGAL/REGULATORY ASPECTS OF HERBAL PRODUCTS

Chapter 1: Legal/Regulatory Aspects of Herbal Products	3
<i>Melanie Johns Cupp</i>	

PART II MONOGRAPHS

Chapter 1: Ma Huang and the <i>Ephedra</i> Alkaloids	11
<i>Steven B. Karch</i>	
1.1 Sources	11
1.2 History and Traditional Uses	11
1.3 Current Promoted Uses	12
1.4 Products Available	13
1.5 Pharmacology	15
1.5.1 Introduction	15
1.5.2 Pharmacologic Effects	16
1.5.3 Metabolism and Elimination	16
1.5.4 Workplace and Sports Drug Testing	17
1.6 Drug Interactions	17
1.7 Toxicology	18
1.7.1 Neurologic Disorders	18
1.7.2 Renal Disorders	20
1.7.3 Cardiovascular Diseases	21
1.7.4 Other Medical Problems and Effects	22

1.8 Postmortem Toxicology	23
1.9 Analytic Considerations	24
1.10 Methamphetamine Manufacture	24
1.11 Commission E Recommendations	25
Chapter 2: Kava	31
<i>Shawn Reeder and Melanie Johns Cupp</i>	
2.1 History and Traditional Uses	31
2.2 Current Promoted Uses	32
2.3 Products Available	32
2.4 Pharmacologic/Toxicologic Effects	32
2.4.1 Neurologic Effects	32
2.4.2 Dermatological Effects	35
2.4.3 Musculoskeletal Effects	36
2.4.4 Antimicrobial Activity	36
2.4.5 Hepatotoxicity	36
2.4.6 Antiplatelet Effects	36
2.5 Case Reports of Toxicity Due to Commercially Available Products	36
2.6 Toxicity Associated with Traditional Use by Native Peoples	37
2.7 Drug Interactions	38
2.8 Pharmacokinetics/Toxicokinetics	38
2.8.1 Absorption	38
2.8.2 Metabolism/Elimination	38
2.9 Analysis of Biofluids	38
2.10 Chemical Analysis	39
2.11 Regulatory Status	39
Chapter 3: <i>Ginkgo biloba</i>	43
<i>Forouzandeh Mahdavi and Melanie Johns Cupp</i>	
3.1 History and Traditional Use	43
3.2 Current Promoted Use	43
3.3 Products Available	43
3.4 Pharmacologic/Toxicologic Effects	44
3.4.1 Nervous System Effects	44
3.4.2 Cardiovascular Effects	46
3.4.3 Carcinogenicity/Mutagenicity/Teratogenicity	46
3.4.4 Endocrine Effects	47
3.5 Case Reports of Toxicity Due to Commercially Available Products	47
3.6 Drug Interactions	48
3.7 Pharmacokinetics/Toxicokinetics	48

3.7.1 Absorption	48
3.7.2 Distribution	49
3.7.3 Metabolism/Elimination	49
3.8 Chemical Analysis	49
3.9 Analysis of Biofluids	50
3.10 Regulatory Status	50
Chapter 4: Valerian	53
<i>Marlea Givens and Melanie Johns Cupp</i>	
4.1 History and/Traditional Uses	53
4.2 Current Promoted Uses	53
4.3 Products Available	54
4.4 Pharmacologic/Toxicologic Effects	54
4.4.1 Central Nervous System Effects	54
4.4.2 Musculoskeletal Effects	59
4.4.3 Reproduction	59
4.4.4 Cardiovascular Effects	60
4.4.5 Cytotoxicity	60
4.5 Case Reports of Toxicity Due to Commercially Available Products	61
4.6 Drug Interactions	63
4.7 Chemical Analysis	64
4.8 Regulatory Status	64
Chapter 5: St. John's Wort	67
<i>John T. Schwarz and Melanie Johns Cupp</i>	
5.1 History and Traditional Uses	67
5.2 Current Promoted Uses	67
5.3 Products Available	68
5.4 Pharmacologic/Toxicologic Effects	68
5.4.1 Neurological Effects	68
5.4.2 Antimicrobial Effects	70
5.4.3 Mutagenicity	70
5.4.4 Reproduction	70
5.5 Adverse Effects and Toxicity	70
5.6 Drug Interactions	72
5.7 Pharmacokinetics/Toxicokinetics	74
5.7.1 Absorption	74
5.7.2 Distribution	75
5.7.3 Metabolism/Elimination	75
5.8 Chemical Analysis	76
5.9 Analysis of Biofluids	76
5.10 Regulatory Status	76

Chapter 6: Chamomile	79
<i>Melanie Johns Cupp</i>	
6.1 History and Traditional Uses	79
6.2 Current Promoted Uses	79
6.3 Products Available	79
6.4 Pharmacologic/Toxicologic Effects	79
6.4.1 Neurologic Effects	79
6.4.2 Antineoplastic Effects	80
6.4.3 Anti-Inflammatory Activity	80
6.5 Case Reports of Toxicity Due to Commercially Available Products	80
6.6 Pharmacokinetics/Toxicokinetics	82
6.7 Analysis of Biofluids	82
6.8 Regulatory Status	82
Chapter 7: <i>Echinacea</i>	85
<i>Julie Davis and Melanie Johns Cupp</i>	
7.1 History and Traditional Uses	85
7.2 Current Promoted Uses	86
7.3 Products Available	86
7.4 Pharmacologic/Toxicologic Effects	86
7.4.1 Immunologic Effects	86
7.4.2 Antimicrobial/Antiviral Effects	87
7.4.3 Antineoplastic Activity	89
7.4.4 Wound-Healing	89
7.4.5 Anti-Inflammatory Effects	90
7.4.6 Mutagenicity/Carcinogenicity	90
7.4.7 Reproduction	90
7.5 Case Reports of Toxicity Due to Commercially Available Products	90
7.6 Chemical Analysis	91
7.7 Regulatory Status	91
Chapter 8: Feverfew	95
<i>Brian Schuller and Melanie Johns Cupp</i>	
8.1 History and Traditional Uses	95
8.2 Current Promoted Uses	95
8.3 Products Available	96
8.4 Pharmacology/Toxicology	97
8.4.1 Neurologic Effects	97
8.4.2 Anti-Inflammatory Effects	100
8.4.3 Mutagenicity/Carcinogenicity/Teratogenicity	101

8.5 Case Reports of Toxicity Due to Commercially Available Products	102
8.6 Drug Interactions	102
8.7 Chemical Analysis	103
8.8 Regulation	103
Chapter 9: Garlic	107
<i>James Allman and Melanie Johns Cupp</i>	
9.1 History and Traditional Uses	107
9.2 Current Promoted Uses	107
9.3 Products Available	107
9.4 Pharmacologic/Toxicologic Effects	109
9.4.1 Cardiovascular Effects	109
9.4.2 Gastrointestinal Effects	112
9.4.3 Antimicrobial Activity	112
9.4.4 Antineoplastic Activity	113
9.4.5 Immunostimulant Activity	114
9.5 Case Reports of Toxicity	115
9.6 Drug Interactions	118
9.7 Pharmacokinetics/Toxicokinetics	118
9.7.1 Absorption	118
9.7.2 Distribution	118
9.7.3 Metabolism/Elimination	118
9.8 Analysis of Biofluids	120
9.9 Regulatory Status	120
Chapter 10: Ginger	123
<i>Charity Metz and Melanie Johns Cupp</i>	
10.1 History and Traditional Uses	123
10.2 Current Promoted Uses	124
10.3 Products Available	124
10.4 Pharmacologic/Toxicologic Effects	125
10.4.1 Gastrointestinal Effects	125
10.4.2 Anti-Inflammatory Activity	126
10.4.3 Use in Migraine	127
10.4.4 Cardiovascular Effects	127
10.4.5 Mutagenicity	128
10.4.6 Reproduction	128
10.5 Case Reports of Toxicity Due to Commercially Available Products	128
10.6 Drug Interactions	129
10.7 Chemical Analysis	129
10.8 Regulatory Status	129

Chapter 11: Saw Palmetto	133
<i>Amy Meadows and Melanie Johns Cupp</i>	
11.1 History and Traditional Uses	133
11.2 Current Promoted Uses	133
11.3 Products Available	134
11.4 Pharmacologic/Toxicologic Effects	134
11.4.1 Immunologic Effects	134
11.4.2 Genitourinary/Endocrine Effects	134
11.4.3 Anti-Inflammatory Effects	136
11.5 Case Reports of Toxicity Due to Commercially Available Products	136
11.6 Pharmacokinetics/Toxicokinetics	137
11.6.1 Absorption	137
11.6.2 Distribution	137
11.6.3 Metabolism/Elimination	137
11.7 Analysis of Biofluids	137
11.8 Chemical Analysis	138
11.9 Regulatory Status	138
Chapter 12: <i>Panax</i> Ginseng	141
<i>Angela Morgan and Melanie Johns Cupp</i>	
12.1 History and Traditional Uses	141
12.2 Current Promoted Uses	142
12.3 Products Available	142
12.4 Pharmacologic/Toxicologic Effects	143
12.4.1 Endocrine Effects	143
12.4.2 Neurologic Effects	144
12.4.3 Cardiovascular Effects	144
12.4.4 Hematologic Effects	144
12.4.5 Immunologic Effects	145
12.4.6 Antineoplastic Effects	146
12.5 Case Reports of Toxicity Due to Commercially Available Products	145
12.6 Drug Interactions	147
12.7 Pharmacokinetics/Toxicokinetics	148
12.7.1 Absorption	148
12.7.2 Distribution	148
12.7.3 Metabolism/Elimination	149
12.8 Analysis of Biofluids	149
12.9 Chemical Analysis	150
12.10 Regulatory Status	150

Chapter 13: Cranberry	155
<i>Angela J. Lawson and Melanie Johns Cupp</i>	
13.1 History and Traditional Uses	155
13.2 Current Promoted Uses	155
13.3 Products Available	155
13.4 Pharmacologic/Toxicologic Effects	157
13.4.1 Antimicrobial Activity	157
13.4.2 Gastrointestinal Effects	158
13.4.3 Renal Effects	158
13.5 Chemical Analysis	159
13.6 Regulatory Status	159
Chapter 14: Borage	161
<i>Melanie Johns Cupp</i>	
14.1 History and Traditional Uses	161
14.2 Current Promoted Uses	162
14.3 Products Available	162
14.4 Pharmacologic/Toxicologic Effects	162
14.4.1 Anti-Inflammatory Effects	162
14.4.2 Dermatologic Effects	165
14.4.3 Respiratory Effects	166
14.4.4 Carcinogenicity	166
14.4.5 Hematologic Effects	166
14.4.6 Effects in Diabetic Neuropathy	166
14.4.7 Cardiovascular Effects	166
14.5 Case Reports of Toxicity	167
14.6 Pharmacokinetics/Toxicokinetics	167
14.7 Chemical Analysis	167
14.8 Regulatory Status	167
Chapter 15: Calamus	171
<i>Melanie Johns Cupp</i>	
15.1 History and Traditional Uses	171
15.2 Current Promoted Uses	172
15.3 Products Available	172
15.4 Pharmacologic/Toxicologic Effects	172
15.4.1 Carcinogenicity	172
15.4.2 Mutagenicity/Genotoxicity	172
15.4.3 Antimicrobial Activity	172
15.4.4 Central Nervous System Effects	172
15.4.5 Musculoskeletal Effects	173

15.4.6 Cardiovascular Effects	173
15.4.7 LD ₅₀	174
15.4.8 Reproductive Effects	174
15.4.9 Local Anesthetic Effects	174
15.5 Case Reports of Toxicity	174
15.6 Chemical Analysis	174
15.7 Regulatory Status	174
Chapter 16: Chaparral	177
<i>Kim Melgarejo and Melanie Johns Cupp</i>	
16.1 History and Traditional Uses	177
16.2 Current Promoted Uses	178
16.3 Products Available	178
16.4 Pharmacologic/Toxicologic Effects	178
16.4.1 Antineoplastic Activity	178
16.4.2 Hepatotoxicity	180
16.4.3 Effects on the Arachidonic Acid Cascade	180
16.4.4 Nephrotoxicity	181
16.4.5 Carcinogenicity	182
16.4.6 Dermatologic Effects	182
16.4.7 Antihyperglycemic Effects	182
16.5 Case Reports of Toxicity Due to Commercially Available Products	182
16.6 Drug Interactions	187
16.7 Pharmacokinetics	187
16.8 Chemical Analysis/Analysis of Biofluids	188
16.9 Regulatory Status	188
Chapter 17: Coltsfoot	191
<i>Amanda Dailey and Melanie Johns Cupp</i>	
17.1 History and Traditional Uses	191
17.2 Current Promoted Uses	191
17.3 Products Available	192
17.4 Pharmacologic/Toxicologic Effects	192
17.4.1 Respiratory Effects	192
17.4.2 Cardiovascular Effects	193
17.4.3 Antimicrobial Effects	193
17.4.4 Hepatotoxicity	193
17.4.5 Carcinogenicity/Genotoxicity	194
17.5 Case Reports of Toxicity Due to Commercially Available Products	195
17.6 LD ₅₀	198
17.7 Pharmacokinetics/Toxicokinetics	198

17.7.1 Absorption	198
17.7.2 Distribution	198
17.7.3 Metabolism/Elimination	198
17.8 Analysis of Biofluids/Chemical Analysis	199
17.9 Regulatory Status	200
Chapter 18: Comfrey	203
<i>David Burch and Melanie Johns Cupp</i>	
18.1 History and Traditional Uses	203
18.2 Current Promoted Uses	204
18.3 Products Available	204
18.4 Pharmacologic/Toxicologic Effects	204
18.4.1 Gastrointestinal Effects	205
18.4.2 Hepatotoxicity	205
18.4.3 Carcinogenicity/Mutagenicity	206
18.4.4 LD ₅₀	207
18.5 Case Reports of Toxicity Due to Commercially Available Products	208
18.6 Drug Interactions	210
18.7 Pharmacokinetics/Toxicokinetics	210
18.7.1 Absorption	210
18.7.2 Distribution	211
18.7.3 Metabolism/Elimination	211
18.8 Analysis of Biofluids	211
18.9 Chemical Analysis	212
18.10 Regulatory Status	212
Chapter 19: Scullcap	215
<i>Jennifer Schumacher and Melanie Johns Cupp</i>	
19.1 History and Traditional Uses	215
19.2 Current Promoted Uses	216
19.3 Products Available	216
19.4 Pharmacologic/Toxicologic Effects	216
19.4.1 Antispasmodic Effects	216
19.4.2 Hepatotoxicity	216
19.4.3 Cardiovascular Effects	216
19.4.4 Antimicrobial Activity	217
19.4.5 Anti-Inflammatory Activity	217
19.4.6 Chemotherapeutic Activity	218
19.5 Case Reports of Toxicity Due to Commercially Available Products	218
19.6 Chemical Analysis	220
19.7 Regulatory Status	220

Chapter 20: Licorice	223
<i>Michael Newton and Melanie Johns Cupp</i>	
20.1 History and Traditional Uses	223
20.2 Current and Promoted Uses	223
20.3 Products Available	224
20.4 Pharmacologic/Toxicologic Effects	224
20.4.1 Respiratory Effects	224
20.4.2 Anti-Inflammatory Effects	224
20.4.3 Adrenocorticotrophic Effects	225
20.4.4 Gastrointestinal Effects	226
20.4.5 Antimicrobial Activity	226
20.5 Case Reports of Toxicity Due to Commercially Available Products	227
20.6 Pharmacokinetics/Toxicokinetics	231
20.6.1 Absorption	231
20.6.2 Distribution	231
20.6.3 Metabolism/Elimination	231
20.6.4 Analysis of Biofluids	232
20.7 Regulatory Status	232
Chapter 21: Pokeweed	237
<i>A. Heather Knight-Trent and Melanie Johns Cupp</i>	
21.1 History and Traditional Uses	237
21.2 Products Available	238
21.3 Pharmacologic/Toxicologic Effects	238
21.3.1 Antimicrobial Activity and Antineoplastic Activity	238
21.3.2 Anti-Inflammatory Activity	238
21.3.3 Cardiovascular Effects	238
21.3.4 Musculoskeletal Effects	239
21.3.5 Gastrointestinal Effects	239
21.3.6 Respiratory Effects	239
21.3.7 Neurologic Effects	239
21.3.8 Hematologic Effects	239
21.4 Case Reports of Toxicity	239
21.5 Pharmacokinetics/Toxicokinetics	242
21.6 Chemical Analysis	242
21.7 Regulatory Status	242
Chapter 22: <i>Sassafras</i>	245
<i>David Hutson and Melanie Johns Cupp</i>	
22.1 History and Traditional Uses	245
22.2 Current Uses	246
22.3 Pharmacologic/Toxicologic Effects	246

22.3.1 Anti-Inflammatory Activity	246
22.3.2 Antineoplastic Activity	246
22.3.3 Carcinogenicity	246
22.3.4 Antimicrobial Activity	247
22.4 Case Reports of Toxicity	248
22.5 Pharmacokinetics/Toxicokinetics	249
22.5.1 Absorption	249
22.5.2 Distribution	249
22.5.3 Metabolism/Elimination	249
22.6 Drug and food Interactions	250
22.7 Analysis of Biofluids	250
22.8 Regulatory Status	251
Chapter 23: Hawthorn.....	253
<i>Jennifer Annon and Melanie Johns Cupp</i>	
23.1 History and Traditional Uses	253
23.2 Current Promoted Uses	254
23.3 Products Available	254
23.4 Pharmacologic/Toxicologic Effects	254
23.4.1 Cardiovascular Effects	254
23.4.2 Neurologic Effects	256
23.4.3 LD ₅₀	256
23.4.4 Teratogenicity/Mutagenicity/Carcinogenicity	256
23.5 Case Reports of Toxicity Due to Commercially Available Products	256
23.6 Pharmacokinetics/Toxicokinetics	257
23.7 Chemical Analysis	257
23.8 Regulatory Status	257
Chapter 24: <i>Aloe</i>	259
<i>Tara Dalton and Melanie Johns Cupp</i>	
24.1 History and Traditional Uses	259
24.2 Current Promoted Uses	260
24.3 Products Available	260
24.4 Pharmacologic/Toxicologic Effects	261
24.4.1 Gastrointestinal Effects	261
24.4.2 Carcinogenicity/Genotoxicity	262
24.4.3 Hematopoietic Activity	262
24.4.4 Antimicrobial Activity	263
24.4.5 Antineoplastic Activity	264
24.4.6 Anti-Inflammatory and Wound Healing Activity	264
24.5 Case Reports of Toxicity Due to Commercially Available Products	266

24.6 Potential Drug Interactions	267
24.7 Pharmacokinetics/Toxicokinetics	267
24.7.1 Absorption	267
24.7.2 Distribution	268
24.7.3 Metabolism/Elimination	268
24.8 Analysis of Biofluids	268
24.9 Regulatory Status	269
Chapter 25: Senna	273
Melanie Johns Cupp	
25.1 History and Chemistry	273
25.2 Current Promoted Uses	274
25.3 Products Available	274
25.4 Pharmacologic/Toxicologic Effects	274
25.4.1 Carcinogenicity/Mutagenicity/Genotoxicity	274
25.4.2 Gastrointestinal Effects	276
25.4.3 Laxative Abuse	278
25.5 Pharmacokinetics/Toxicokinetics	278
25.5.1 Absorption	278
25.5.2 Distribution	279
25.5.3 Metabolism/Elimination	279
25.6 Chemical Analysis	279
25.7 Analysis of Biofluids	279
25.8 Regulatory Status	280
Chapter 26: Cascara Sagrada	283
Amy Renner and Melanie Johns Cupp	
26.1 History and Traditional Uses	283
26.2 Current Promoted Uses	283
26.3 Products Available	283
26.4 Pharmacologic/Toxicologic Effects	284
26.4.1 Gastrointestinal Effects	284
26.4.2 Nutritional/Metabolic Effects	284
26.4.3 Carcinogenicity/Mutagenicity/Genotoxicity	284
26.5 Case Reports of Toxicity Due to Commercially Available Products	285
26.6 Drug Interactions	285
26.7 Pharmacokinetics/Toxicokinetics	285
26.8 Analysis of Biofluids	286
26.9 Chemical Analysis	286
26.10 Regulatory Status	286

Chapter 27: Dong Quai	289
<i>Rayna De Rosa and Melanie Johns Cupp</i>	
27.1 History and Traditional Uses	289
27.2 Current Promoted Uses	289
27.3 Products Available	289
27.4 Pharmacologic/Toxicologic Effects	290
27.4.1 Cardiovascular Effects	290
27.4.2 Neurologic Effects	290
27.4.3 Musculoskeletal Effects	290
27.4.4 Immunologic Effects/Antineoplastic Activity/Antimicrobial Activity	291
27.4.5 Anit-Inflammatory Activity	291
27.4.6 Dermatological Effects	291
27.4.7 Carcinogenicity	291
27.4.8 Estrogenic Effects	292
27.4.9 Gastrointestinal Effects	292
27.5 Drug Interactions	292
27.6 Chemical Analysis	293
27.7 Regulatory Status	293
Chapter 28: Cat's Claw	295
<i>Melissa Dawn Bostic and Melanie Johns Cupp</i>	
28.1 History and Traditional Uses	295
28.2 Current Promoted Uses	295
28.3 Products Available	296
28.4 Pharmacologic/Toxicologic Effects	296
28.4.1 Antiviral Effects	296
28.4.2 Antineoplastic Activity	296
28.4.3 Antimutagenic Activity	296
28.4.4 Cytotoxicity	297
28.5 Case Reports of Toxicity Due to Commercially Available Products	297
28.6 Regulatory Status	297
PART III SUMMARY OF TOXICITIES AND DRUG INTERACTIONS	
Chapter 1: Summary of Toxicities and Drug Interactions	301
<i>Melanie Johns Cupp</i>	
Index	303



<http://www.springer.com/978-0-89603-791-5>

Toxicology and Clinical Pharmacology of Herbal
Products

Cupp, M.J.

2000, XXVI, 325 p., Hardcover

ISBN: 978-0-89603-791-5

A product of Humana Press